PubMed Health⌕ Search

PubMed · 3540587

Hormones and epilepsy.

Abstract

The complex interactions of neurosecretions with the developing brain suggest that it has multiple site and time-specific vulnerabilities that may contribute to the pathogenesis of several forms of epilepsy, yet, on the other hand, may provide several new forms of therapy. Catamenial seizures can be clearly related to hormonal changes, although other factors are important, such as altered drug metabolism during menses. Progesterone appears to be especially effective in treating seizures. Optimal forms of treatment for catamenial epilepsy have not been established; however, several forms of progesterone are available and may be helpful, including those in oral contraceptives. Special care in the selection of oral contraceptives may be an important adjunct in caring for women with epilepsy. Altered secretion of neurohormones suggests important clues to the sexual dysfunction and psychopathology associated with temporal lobe epilepsy. New approaches to these patients include the clinical evaluation for sexual dysfunction along with the measurement of prolactin, testosterone, LH, and FSH levels, and treatment of sexual dysfunction by the effective use of anticonvulsants. Elevated plasma hormones (especially prolactin) following seizures can help to distinguish true seizures from pseudoseizures. Effects of anticonvulsant drugs on endocrine function are important, particularly with respect to their ability to lower the efficacy of oral contraceptives by competitive binding. A number of hormonal changes have been described with several drugs, which suggest that their complex central and peripheral effects might help to explain some aspects of normal hormone activity as well as some common side effects of the drugs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A W Zimmerman. 1986. Hormones and epilepsy.. https://pubmed.ncbi.nlm.nih.gov/3540587/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗